Precision medicine provides a framework for implementing tools and practices that incorporate granular and intersecting patient attributes into nuanced interventions that optimize for person-level health outcomes. In the domain of opioid prescribing and stewardship, first-to-market tools with single-sided, risk-based scoring frameworks and a narrow focus on behavioral compliance and metabolic efficiency threaten to crowd out a new generation of tools. Providing several advantages, the new tools assess both risks and benefits of opioid analgesic treatments—as well as the risks and benefits of withholding those treatments.
In addition to a wider scope of clinical endpoints and influences, the next generation of precision medicine supports for opioid prescribing should leverage growing research on the use of artificial intelligence (AI) and machine learning (ML) to evaluate and optimize fairness in clinical decision supports. As a hedge against historical disparities and stigmas that have undermined patient outcomes—and as an alternative to first-to-market tools designed for behavioral surveillance and control—Booz Allen strives to integrate and validate precision medicine frameworks that prioritize equity and optimize holistic health outcomes for patients embedded in communities where they live and seek to thrive.